Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jul;115(6):945–952. doi: 10.1111/j.1476-5381.1995.tb15902.x

A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

J P Hannon 1, H J Pfannkuche 1, J R Fozard 1
PMCID: PMC1909004  PMID: 7582525

Abstract

1. The adenosine A3 receptor agonist, N6-2-(4-aminophenyl)ethyladenosine (APNEA) induces hypotension in the anaesthetized rat. The present experiments were carried out to explore the role of mast cells in the response. 2. Intravenous injection of APNEA (1-30 micrograms kg-1 to rats in which the A3 receptor-mediated response had been isolated by pretreatment with 8-(p-sulphophenyl) theophylline (8-SPT)), induced dose-related falls in blood pressure accompanied at higher doses by small falls in heart rate. Responses to the mast cell degranulating agent, compound 48/80 (10-300 micrograms kg-1, i.v.) were qualitatively similar to those to APNEA. 3. Pretreatment with sodium cromoglycate (0.25-20 mg kg-1, i.v.) induced dose-related, although incomplete, blockade of the hypotensive responses to APNEA. At 20 mg kg-1, sodium cromoglycate also inhibited the cardiovascular response to compound 48/80 but had no effects on those to the selective A1 receptor agonist, N6-cyclopentyladenosine (CPA) or the selective A2A receptor agonist, 2-[p-(2-carboxyethyl)phenylamino]-5'-N-ethylcarboxamidoadenosine (CGS 21680). Lodoxamide (0.01-20 mg kg-1) also blocked selectively but incompletely the response to APNEA. 4. The cardiovascular responses to compound 48/80 (10-300 micrograms kg-1, i.v.) were markedly suppressed in animals which had received repeated doses of the compound by the intraperitoneal route. Similarly APNEA was essentially devoid of cardiovascular activity in such preparations. In contrast, responses to CPA were similar in animals treated repeatedly with compound 48/80 to those obtained in control animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
945

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali H., Cunha-Melo J. R., Saul W. F., Beaven M. A. Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor. J Biol Chem. 1990 Jan 15;265(2):745–753. [PubMed] [Google Scholar]
  2. Ali H., Müller C. E., Daly J. W., Beaven M. A. Methylxanthines block antigen-induced responses in RBL-2H3 cells independently of adenosine receptors or cyclic AMP: evidence for inhibition of antigen binding to IgE. J Pharmacol Exp Ther. 1991 Sep;258(3):954–962. [PubMed] [Google Scholar]
  3. Banks B. E., Dempsey C. E., Vernon C. A., Warner J. A., Yamey J. Anti-inflammatory activity of bee venom peptide 401 (mast cell degranulating peptide) and compound 48/80 results from mast cell degranulation in vivo. Br J Pharmacol. 1990 Feb;99(2):350–354. doi: 10.1111/j.1476-5381.1990.tb14707.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Björck T., Gustafsson L. E., Dahlén S. E. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis. 1992 May;145(5):1087–1091. doi: 10.1164/ajrccm/145.5.1087. [DOI] [PubMed] [Google Scholar]
  5. Brogden R. N., Speight T. M., Avery G. S. Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use. Drugs. 1974;7(3):164–282. doi: 10.2165/00003495-197407030-00002. [DOI] [PubMed] [Google Scholar]
  6. Carruthers A. M., Fozard J. R. Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat. Eur J Pharmacol. 1993 Nov 30;250(1):185–188. doi: 10.1016/0014-2999(93)90641-t. [DOI] [PubMed] [Google Scholar]
  7. Chapman I. D., Kristersson A., Mathelin G., Schaeublin E., Mazzoni L., Boubekeur K., Murphy N., Morley J. Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423–429. doi: 10.1111/j.1476-5381.1992.tb14350.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Di Rosa M., Giroud J. P., Willoughby D. A. Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J Pathol. 1971 May;104(1):15–29. doi: 10.1002/path.1711040103. [DOI] [PubMed] [Google Scholar]
  9. Doyle M. P., Linden J., Duling B. R. Nucleoside-induced arteriolar constriction: a mast cell-dependent response. Am J Physiol. 1994 May;266(5 Pt 2):H2042–H2050. doi: 10.1152/ajpheart.1994.266.5.H2042. [DOI] [PubMed] [Google Scholar]
  10. Enerbäck L., Svensson I. Isolation of rat peritoneal mast cells by centrifugation on density gradients of Percoll. J Immunol Methods. 1980;39(1-2):135–145. doi: 10.1016/0022-1759(80)90302-6. [DOI] [PubMed] [Google Scholar]
  11. Fozard J. R., Carruthers A. M. Adenosine A3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol. 1993 May;109(1):3–5. doi: 10.1111/j.1476-5381.1993.tb13522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fozard J. R., Carruthers A. M. The cardiovascular effects of selective adenosine A1 and A2 receptor agonists in the pithed rat: no role for glibenclamide-sensitive potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):192–196. doi: 10.1007/BF00169266. [DOI] [PubMed] [Google Scholar]
  13. Gallo-Rodriguez C., Ji X. D., Melman N., Siegman B. D., Sanders L. H., Orlina J., Fischer B., Pu Q., Olah M. E., van Galen P. J. Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists. J Med Chem. 1994 Mar 4;37(5):636–646. doi: 10.1021/jm00031a014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson H. G., VanHout C. A., Wright J. B. Inhibition of allergic reactions by cromoglycate and by a new anti-allergy drug U-42,585E. I. Activity in rats. Int Arch Allergy Appl Immunol. 1978;56(5):416–423. doi: 10.1159/000232051. [DOI] [PubMed] [Google Scholar]
  15. Marquardt D. L., Parker C. W., Sullivan T. J. Potentiation of mast cell mediator release by adenosine. J Immunol. 1978 Mar;120(3):871–878. [PubMed] [Google Scholar]
  16. Marquardt D. L., Wasserman S. I. [3H]Adenosine binding to rat mast cells--pharmacologic and functional characterization. Agents Actions. 1985 Sep;16(6):453–461. doi: 10.1007/BF01983646. [DOI] [PubMed] [Google Scholar]
  17. PATON W. D. M. Compound 48/80: a potent histamine liberator. Br J Pharmacol Chemother. 1951 Sep;6(3):499–508. doi: 10.1111/j.1476-5381.1951.tb00661.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pauwels R. A., Van der Straeten M. E. An animal model for adenosine-induced bronchoconstriction. Am Rev Respir Dis. 1987 Aug;136(2):374–378. doi: 10.1164/ajrccm/136.2.374. [DOI] [PubMed] [Google Scholar]
  19. Qian Y. X., McCloskey M. A. Activation of mast cell K+ channels through multiple G protein-linked receptors. Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7844–7848. doi: 10.1073/pnas.90.16.7844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ramkumar V., Stiles G. L., Beaven M. A., Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993 Aug 15;268(23):16887–16890. [PubMed] [Google Scholar]
  21. Tanizaki Y., Ohtani J., Kimura I. Actions and cross-reactivity of antiallergic agents and a calcium channel antagonist on rat peritoneal mast cells. Difference in the action mechanisms and cross-reactivity among the agents. Agents Actions. 1992 Sep;37(1-2):8–15. doi: 10.1007/BF01987884. [DOI] [PubMed] [Google Scholar]
  22. Zhou Q. Y., Li C., Olah M. E., Johnson R. A., Stiles G. L., Civelli O. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432–7436. doi: 10.1073/pnas.89.16.7432. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES